A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment

Zhangyang Bi,Yayun Wang,Wei Zhang

DOI: https://doi.org/10.1016/j.biopha.2021.111404

2021-05-01

Abstract:<p>Tanshinone IIA (Tan IIA) is the most abundant lipid-soluble component in Salvia miltiorrhiza. Both Tan IIA and its derivatives including Sodium tanshinone IIA sulfonate (STS) have been widely used in clinic due to their proved anti-inflammation, anti-oxidation, and anti-fibrosis functions. Recently, combinations containing Tan IIA and active components have attracted intensive interest in fibrosis. Multiple studies have been conducted to attempt to decipher the mechanisms of this traditional Chinese medicine and found that Tan IIA can attenuate fibrosis through different pathways such as Smad2/3, NF-κB, Nrf2, E2F and snail/twist axis. However, some of the studies were contradictory and confusing. Therefore, it was important to develop an easy-to-access reference for clinic use. In this study, we reviewed the pharmacological mechanisms, pharmacokinetics, and toxicology of Tan IIA and its derivatives in the treatment of fibrosis and introduced the cutting-edge new formulation of Tan IIA compound.</p>

pharmacology & pharmacy,medicine, research & experimental

What problem does this paper attempt to address?

This paper aims to comprehensively review the application of tanshinone IIA (Tan IIA) and its derivatives in the treatment of fibrotic diseases. Specifically, the paper attempts to address the following issues:

1. **Clarify the pharmacological mechanisms of tanshinone IIA and its derivatives**: The paper elaborately explores how tanshinone IIA exerts anti - fibrotic effects through multiple signaling pathways (such as Smad2/3, NF - κB, Nrf2, E2F and snail/twist axis, etc.), and these pathways play a crucial role in the fibrosis of multiple organs such as the lung, heart, liver, kidney and uterus.

2. **Evaluate the pharmacokinetic and toxicological characteristics of tanshinone IIA and its derivatives**: The paper analyzes the metabolic process, distribution situation and potential toxicity of tanshinone IIA and its derivatives in vivo, which is of great significance for the safety and effectiveness of clinical applications.

3. **Introduce new dosage forms of tanshinone IIA**: Due to the problems of low solubility and poor oral bioavailability of tanshinone IIA, the paper also introduces new methods to improve its efficacy through nanotechnology (such as nanoparticles NPs).

4. **Provide clinical references**: In view of some contradictions and confusions in existing research, the paper aims to provide an easily accessible reference for clinicians to better understand and apply the potential of tanshinone IIA and its derivatives in the treatment of fibrosis.

In conclusion, the main objective of this paper is to systematically summarize the pharmacological mechanisms, pharmacokinetics, toxicological characteristics and new dosage forms of tanshinone IIA and its derivatives in the treatment of fibrosis, and provide a scientific basis for clinical applications.